Q2 2025 Praxis Precision Medicines Inc Earnings Call Transcript
Key Points
- Praxis Precision Medicines Inc (PRAX) reported best-in-disease efficacy for Vormatrigine in the RADIANT study, with a median seizure reduction of over 56%.
- 60% of patients achieved at least a 50% reduction in seizures, with 22% of patients being completely seizure-free during the second month of treatment.
- Vormatrigine demonstrated a favorable safety profile, with most adverse events being mild to moderate and resolving over time.
- The company has a robust pipeline with multiple readouts expected in the next several quarters, supported by a cash runway extending into 2028.
- Praxis Precision Medicines Inc (PRAX) is planning to include a depression and mood endpoint in the POWER2 study, based on observed positive impacts on mood in the RADIANT study.
- The RADIANT study observed a 23% discontinuation rate, often linked to a lack of background ASM dose adjustment.
- Despite the positive results, the company acknowledges the need for better management of background therapies to reduce discontinuation rates.
- The study's success is contingent on effective recruitment, which remains a challenge in the competitive landscape of epilepsy trials.
- The company faces the challenge of proving Vormatrigine's efficacy in a highly refractory patient population, which could impact placebo rates in future studies.
- There is a need for additional data to support Vormatrigine's use as a monotherapy, which could require further studies and delay market entry.
Good day, and welcome to the Praxis Precision Medicine's RADIANT top line results and second-quarter 2025 financial results conference call. (Operator Instructions) As a reminder, this call may be recorded.
I would now like to turn the call over to Dan Ferry of LifeSci Advisors. Please go ahead.
Good morning, and welcome to the Praxis Precision Medicine's RADIANT top line results and second quarter 2025 financial results conference. This call is being webcast live and can be accessed on the Investors section of the Praxis website at www.praxismedicines.com.
Please note that remarks made during this call may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These may include statements about the company's future expectations and plans, clinical development time lines and financial projections. While these forward-looking statements represent Praxis' views as
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
